Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2017

06.06.2017 | Research Article

Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia

verfasst von: Z. Wu, R. Chen, L. Wu, L. Zou, F. Ding, M. Wang, X. Liu

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

As a desmoplastic reaction, tissue fibrosis played crucial roles in solid tumor progression, chemo-resistance, and consequently heralded poor clinical outcome. Previous studies implied the effects of marrow fibrosis on prognosis for acute lymphoblastic leukemia were disputable. In this study, we aimed to investigate the potential role of bone marrow fibrosis on clinical survival in acute myeloid leukemia (AML) patients.

Methods

Bone marrow fibrosis (evaluated as reticulin fiber density, RFD) in bone marrow sections was evaluated at diagnosis via computer technology. Receiver operating characteristic curve (ROC) was used to analyze the predictive value of RFD for relapse and survival status. Kaplan–Meier method was used to estimate survival rates per subgroup between patients with different RFD. Cox proportional hazard regression was used to model the overall survival.

Results

High RFD at diagnosis in bone marrow sections from primary AML might predict early relapse and shorter survival (P = 0.003 and 0.001, respectively). The optimal cutoff value of RFD at diagnosis was determined to be 7.2%. Furthermore, the Kaplan–Meier analysis indicated that patients with high marrow RFD had shorter relapse-free survival (RFS) and overall survival (OS) than patients with low RFD (P = 0.007 and 0.000, respectively). Multivariate analysis suggested that similar with cytogenetics, marrow RFD at diagnosis was an independent prognostic factor for RFS [HR 0.564, 95% confidence interval (CI) 0.338–0.940, P = 0.028] and OS (HR 0.457, 95% CI 0.225–0.929, P = 0.031) in primary AML patients.

Conclusions

Our data suggest that marrow RFD before treatment should be seemed as prognostic factor in primary AML, it may provide valuable clues for developing new targeted therapy.
Literatur
5.
Zurück zum Zitat Wu Z, Yu Y, Zhang J, Zhai Y, Tao Y, Shi J. Clustered immature myeloid precursors in intertrabecular region during remission evolve from leukemia stem cell near endosteum and contribute to disease relapse in acute myeloid leukemia. Med Hypotheses. 2013;80(5):624–8. doi:10.1016/j.mehy.2013.02.005.CrossRefPubMed Wu Z, Yu Y, Zhang J, Zhai Y, Tao Y, Shi J. Clustered immature myeloid precursors in intertrabecular region during remission evolve from leukemia stem cell near endosteum and contribute to disease relapse in acute myeloid leukemia. Med Hypotheses. 2013;80(5):624–8. doi:10.​1016/​j.​mehy.​2013.​02.​005.CrossRefPubMed
6.
Zurück zum Zitat Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–21.CrossRefPubMed Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–21.CrossRefPubMed
9.
Zurück zum Zitat Ueno H, Konishi T, Ishikawa Y, Shimazaki H, Ueno M, Aosasa S, et al. Histologic categorization of fibrotic cancer stroma in the primary tumor is an independent prognostic index in resectable colorectal liver metastasis. Am J Surg Pathol. 2014;38(10):1380–6. doi:10.1097/PAS.0000000000000232.CrossRefPubMed Ueno H, Konishi T, Ishikawa Y, Shimazaki H, Ueno M, Aosasa S, et al. Histologic categorization of fibrotic cancer stroma in the primary tumor is an independent prognostic index in resectable colorectal liver metastasis. Am J Surg Pathol. 2014;38(10):1380–6. doi:10.​1097/​PAS.​0000000000000232​.CrossRefPubMed
10.
Zurück zum Zitat Buesche G, Georgii A, Duensing A, Schmeil A, Schlue J, Kreipe HH. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol. 2003;34(4):391–401.CrossRefPubMed Buesche G, Georgii A, Duensing A, Schmeil A, Schlue J, Kreipe HH. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol. 2003;34(4):391–401.CrossRefPubMed
11.
Zurück zum Zitat Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol. 2001;19(12):2994–3009.CrossRefPubMed Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol. 2001;19(12):2994–3009.CrossRefPubMed
12.
13.
Zurück zum Zitat Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–62. doi:10.1200/JCO.2008.18.2246.CrossRefPubMed Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–62. doi:10.​1200/​JCO.​2008.​18.​2246.CrossRefPubMed
14.
Zurück zum Zitat Norén-Nyström U, Roos G, Bergh A, Forestier E. Prognostic impact of vascular density and fibrosis in the bone marrow of children with high-risk acute lymphoblastic leukemia. Leukemia. 2005;19(11):1998–2001.CrossRefPubMed Norén-Nyström U, Roos G, Bergh A, Forestier E. Prognostic impact of vascular density and fibrosis in the bone marrow of children with high-risk acute lymphoblastic leukemia. Leukemia. 2005;19(11):1998–2001.CrossRefPubMed
15.
Zurück zum Zitat Norén-Nyström U, Roos G, Bergh A, Botling J, Lönnerholm G, Porwit A, et al. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia. 2008;22(3):504–10.CrossRefPubMed Norén-Nyström U, Roos G, Bergh A, Botling J, Lönnerholm G, Porwit A, et al. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia. 2008;22(3):504–10.CrossRefPubMed
16.
Zurück zum Zitat Bharos A, Jong AJ, Manton N, Venn N, Story C, Hodge G, et al. Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia. Leukemia. 2010;24(8):1537–8. doi:10.1038/leu.2010.134.CrossRefPubMed Bharos A, Jong AJ, Manton N, Venn N, Story C, Hodge G, et al. Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia. Leukemia. 2010;24(8):1537–8. doi:10.​1038/​leu.​2010.​134.CrossRefPubMed
17.
Zurück zum Zitat Thomas X, Le QH, Danaïla C, Lhéritier V, Ffrench M. Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors. Leuk Res. 2002;26(10):909–18.CrossRefPubMed Thomas X, Le QH, Danaïla C, Lhéritier V, Ffrench M. Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors. Leuk Res. 2002;26(10):909–18.CrossRefPubMed
18.
Zurück zum Zitat Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–9.CrossRefPubMed Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–9.CrossRefPubMed
21.
Zurück zum Zitat Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia. 2014;28(4):904–16. doi:10.1038/leu.2013.254.CrossRefPubMed Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia. 2014;28(4):904–16. doi:10.​1038/​leu.​2013.​254.CrossRefPubMed
24.
Zurück zum Zitat Wäster P, Rosdahl I, Gilmore BF, Seifert O. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts: implications for melanoma invasion. Int J Oncol. 2011;39(1):193–202. doi:10.3892/ijo.2011.1002.PubMed Wäster P, Rosdahl I, Gilmore BF, Seifert O. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts: implications for melanoma invasion. Int J Oncol. 2011;39(1):193–202. doi:10.​3892/​ijo.​2011.​1002.PubMed
26.
Zurück zum Zitat Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget. 2016;7(5):6159–74. doi:10.18632/oncotarget.6740.CrossRefPubMed Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget. 2016;7(5):6159–74. doi:10.​18632/​oncotarget.​6740.CrossRefPubMed
33.
Zurück zum Zitat Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, et al. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. Eur J Haematol. 2015;94(4):355–62. doi:10.1111/ejh.12438.CrossRefPubMed Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, et al. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. Eur J Haematol. 2015;94(4):355–62. doi:10.​1111/​ejh.​12438.CrossRefPubMed
Metadaten
Titel
Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia
verfasst von
Z. Wu
R. Chen
L. Wu
L. Zou
F. Ding
M. Wang
X. Liu
Publikationsdatum
06.06.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1687-1

Weitere Artikel der Ausgabe 12/2017

Clinical and Translational Oncology 12/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.